Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Pulmonology
•
Pulmonary Infections
•
Non-Tubercular Mycobacteria
Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?
Answer from: at Academic Institution
No, not at this time. Intriguing, but not sure we know enough yet.
Sign in or Register to read more
Answer from: at Academic Institution
I ordered it once but it didn’t help in the diagnosis. The patient expired from multiple organ dysfunction syndrome (MODS) and sepsis. It is an expensive test, so I won’t be ordering it routinely.
Sign in or Register to read more
16531
16652
Related Questions
What is your preferred third antimicrobial agent for a patient with treatment-naive pulmonary MAC without cavitary disease and strict contraindications to utilization of rifampin or rifabutin?
In which patients do you prefer daily standard three-drug therapy for non-cavitary pulmonary MAC as opposed to three times a week dosing?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Do you administer prophylactic antibiotics to prevent VAP following intubation in patients with acute brain injury?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Is there a role for chronic suppressive oral or inhaled therapy for recurrent Burkholderia cepacia pneumonia causing frequent hospitalizations in a patient with severe bronchiectasis with or without underlying cystic fibrosis?
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
Would you treat a sputum culture positive for Aspergillus niger despite an atypical CT chest and a negative serum galactomannan in an immunosuppressed patient who is too high risk for bronchoscopy?
Do you use steroids in the management of PJP pneumonia with severe hypoxia in HIV negative patients?